Research Article Cites HemogloBind™ for Removing Colorimetric Assay Interferences

News Release

Research Article Cites HemogloBind™ for Removing Colorimetric Assay Interferences

MONMOUTH JUNCTION, NJ, July 28, 2016 -- Biotech Support Group reports on a recent research article describing the simplicity and efficiency of their hemoglobin depletion technology for removing colorimetric interferences in measuring cholinesterase activity. The citation is:

Thomas H. Snider, Kevin G. McGarry, Michael C. Babin, David A. Jett, Gennady E. Platoff Jr., and David T. Yeung. Acute Toxicity of Phorate Oxon by oral gavage in the Sprague-Dawley rat. Fundam. Toxicol. Sci. Vol. 3, No.5, 195-204, 2016.

The article describes studies of the oral toxicity of Phorate Oxon with emphasis on gender and age-related effects in rats. The authors used HemogloBind™ as part of the protocol to measure cholinesterase activity. The article states “…80 µl aliquots of whole blood were removed, diluted and treated with HemogloBind™ to remove hemoglobin for later assay to detect cholinesterase activity…

“This is now the 5th research article validating the removal efficiency of HemogloBind™ for depleting hemoglobin prior to cholinesterase measurements. The colorimetric interferences of hemoglobin are quite common in many enzymatic assays so these studies are consistent in that they all show an exquisite selectivity profile in many different animals” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information on HemogloBind™, visit:

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to


Dr. Swapan Roy & Matthew Kuruc
Biotech Support Group LLC
1 Deer Park Drive, Suite M
Monmouth Junction NJ 08852
732-274-2866 Worldwide
800-935-0628 North America